Essential role of CD155 glycosylation in functional binding to DNAM-1 on natural killer cells

被引:0
|
作者
Tahara, Saeko [1 ,2 ]
Okumura, Genki [1 ,3 ]
Matsuo, Tomohei [1 ,4 ]
Shibuya, Akira [1 ,5 ,6 ]
Shibuya, Kazuko [1 ,6 ]
机构
[1] Univ Tsukuba, Inst Med, Dept Immunol, Tsukuba, Ibaraki 3058577, Japan
[2] Univ Tsukuba, Sch Med, Tsukuba, Ibaraki 3058577, Japan
[3] Univ Tsukuba, Doctoral Program Biomed Sci, Comprehens Human Sci, Tsukuba, Ibaraki 3058577, Japan
[4] Univ Tsukuba, Doctoral Program Clin Sci, Comprehens Human Sci, Tsukuba, Ibaraki 3058577, Japan
[5] Univ Tsukuba, Life Sci Ctr Survival Dynam, Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan
[6] Univ Tsukuba, R&D Ctr Innovat Drug Discovery, Tsukuba, Ibaraki 3058577, Japan
关键词
NK cell activation; N-linked glycosylation; posttranslational modification; PVR; TIGIT; OVEREXPRESSION; POLIOVIRUS; ADHESION; RECEPTOR; TIGIT; EXPRESSION;
D O I
10.1093/intimm/dxae005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The cluster of differentiation 155 (CD155) is highly expressed on tumor cells and augments or inhibits the cytotoxic activities of natural killer (NK) cells and T cells through its receptor ligands DNAX accessory molecule 1 (DNAM-1) and T-cell immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT), respectively. Although CD155 is heavily glycosylated, the role of glycosylation of CD155 in the cytotoxic activity of effector lymphocytes remains unknown. Here, we show that the N-linked glycosylation at residue 105 (N105 glycosylation) in the first Ig-like domain of CD155 is involved in the binding of CD155 to both DNAM-1 and TIGIT. The N105 glycosylation also plays an essential role to induce signaling in both DNAM-1 and TIGIT reporter cells. Moreover, we show that the N105 glycosylation of CD155 contributes preferentially to the DNAM-1-mediated activating signal over the TIGIT-mediated inhibitory signal in NK cells. Our results demonstrated the important role of the N105 glycosylation of CD155 in DNAM-1 and TIGIT functions and shed new light on the understanding of tumor immune responses. Graphical Abstract
引用
收藏
页码:317 / 325
页数:9
相关论文
共 50 条
  • [31] Immune checkpoint molecule DNAM-1/CD112 axis is a novel target for natural killer-cell therapy in acute myeloid leukemia
    Kaito, Yuta
    Sugimoto, Emi
    Nakamura, Fumi
    Tsukune, Yutaka
    Sasaki, Makoto
    Yui, Shunsuke
    Yamaguchi, Hiroki
    Goyama, Susumu
    Nannya, Yasuhito
    Mitani, Kinuko
    Tamura, Hideto
    Imai, Yoichi
    HAEMATOLOGICA, 2024, 109 (04) : 1107 - 1120
  • [32] Impaired DNAM-1/CD155 interaction in MS disrupts NK-mediated immune regulation of T-cell activity and is reconstituted by therapeutic modulation of the IL-2 receptor
    Gross, C. C.
    Schulte-Mecklenbeck, A.
    Ruenzi, A.
    Kuhlmann, T.
    Posevitz-Fejfar, A.
    Schwab, N.
    Schneider-Hohendorf, T.
    Held, K.
    Konjevic, M.
    Dornmair, K.
    Hohlfeld, R.
    Elkins, J.
    Ziemssen, T.
    Meuth, S. G.
    Wiendl, H.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 803 - 804
  • [33] Human Induced Pluripotent Stem Cells Are Targets for Allogeneic and Autologous Natural Killer (NK) Cells and Killing Is Partly Mediated by the Activating NK Receptor DNAM-1
    Kruse, Vanessa
    Hamann, Carina
    Monecke, Sebastian
    Cyganek, Lukas
    Elsner, Leslie
    Huebscher, Daniela
    Walter, Lutz
    Streckfuss-Boemeke, Katrin
    Guan, Kaomei
    Dressel, Ralf
    PLOS ONE, 2015, 10 (05):
  • [34] Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D
    Sayitoglu, Ece Canan
    Georgoudaki, Anna-Maria
    Chrobok, Michael
    Ozkazanc, Didem
    Josey, Benjamin J.
    Arif, Muhammad
    Kusser, Kim
    Hartman, Michelle
    Chinn, Tamara M.
    Potens, Renee
    Pamukcu, Cevriye
    Krueger, Robin
    Zhang, Cheng
    Mardinoglu, Adil
    Alici, Evren
    Temple, Harry Thomas
    Sutlu, Tolga
    Duru, Adil Doganay
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [35] Immunoreceptor TIGIT inhibits the cytotoxicity of human cytokine-induced killer cells by interacting with CD155
    Baofu Zhang
    Weina Zhao
    Huizhong Li
    Yuanyuan Chen
    Hui Tian
    Liantao Li
    Longzhen Zhang
    Chao Gao
    Junnian Zheng
    Cancer Immunology, Immunotherapy, 2016, 65 : 305 - 314
  • [36] Immunoreceptor TIGIT inhibits the cytotoxicity of human cytokine-induced killer cells by interacting with CD155
    Zhang, Baofu
    Zhao, Weina
    Li, Huizhong
    Chen, Yuanyuan
    Tian, Hui
    Li, Liantao
    Zhang, Longzhen
    Gao, Chao
    Zheng, Junnian
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2016, 65 (03) : 305 - 314
  • [37] Downregulation of natural killer cell-activating ligand CD155 by human cytomegalovirus UL141
    Tomasec, P
    Wang, ECY
    Davison, AJ
    Vojtesek, B
    Armstrong, M
    Griffin, C
    McSharry, BP
    Morris, RJ
    Llewellyn-Lacey, S
    Rickards, C
    Nomoto, A
    Sinzger, C
    Wilkinson, GWG
    NATURE IMMUNOLOGY, 2005, 6 (02) : 181 - 188
  • [38] Cancer related fibroblasts (CAFs) control killer activity of natural killer cell through the poliovirus receptor (PVR: CD155) and have an important role for tumor expansion
    Inoue, Tomoko
    Kawana, Kei
    Adachi, Katsuyuki
    Taguchi, Ayumi
    Nagamatsu, Ken
    Sato, Masakazu
    Yoshida, Mitsuyo
    Takahashi, Juri
    Fujimoto, Asaha
    Kamoto, Hiroe
    Yamashita, Aki
    Nagasaka, Kazunori
    Osuga, Yutaka
    Fujii, Tomoyuki
    JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2015, 112 : 129 - 129
  • [39] DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy
    Sanchez-Correa, Beatriz
    Valhondo, Isabel
    Hassouneh, Fakhri
    Lopez-Sejas, Nelson
    Pera, Alejandra
    Bergua, Juan M.
    Jose Arcos, Maria
    Banas, Helena
    Casas-Aviles, Ignacio
    Duran, Esther
    Alonso, Corona
    Solana, Rafael
    Tarazona, Raquel
    CANCERS, 2019, 11 (06)
  • [40] Role of NKG2D, DNAM-1 and natural cytotoxicity receptors in cytotoxicity toward rhabdomyosarcoma cell lines mediated by resting and IL-15-activated human natural killer cells
    Gerharda H. Boerman
    Monique M. van Ostaijen-ten Dam
    Kathelijne C. J. M. Kraal
    Susy J. Santos
    Lynne M. Ball
    Arjan C. Lankester
    Marco W. Schilham
    R. Maarten Egeler
    Maarten J. D. van Tol
    Cancer Immunology, Immunotherapy, 2015, 64 : 573 - 583